A randomized, open-label, parallel group study to evaluate the efficacy and safety of the oral administration of Bifidobacterium animalis subsp. lactis LKM512 in patients with atopic dermatitis
Not Applicable
- Conditions
- Atopic dermatitis
- Registration Number
- JPRN-UMIN000005695
- Lead Sponsor
- Kyodo Milk Industry Co. Ltd.
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 50
Inclusion Criteria
Not provided
Exclusion Criteria
(1) Patients who are taking oral Bifidobacteria LKM512 daily (2) Patients who were diagnosed as having milk allergy (3) Patients who was enrolled in other trails within a month. (4) Inappropriate cases evaluated by doctors
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Score of itch after 4 weeks and 8 weeks of administration
- Secondary Outcome Measures
Name Time Method Improvement of dermatological symptoms QOL Intestinal microbiota